Full-Time

Associate Director Commercial Field Trainer

Updated on 4/19/2025

Acadia Pharmaceuticals

Acadia Pharmaceuticals

501-1,000 employees

Develops therapies for neurological disorders

Compensation Overview

$151k - $188.3k/yr

+ Bonus + Equity Awards

Senior

Princeton, NJ, USA + 1 more

More locations: San Diego, CA, USA

Hybrid model requires this role to work in our office three days per week on average.

Category
Training
Requirements
  • A bachelor’s degree (science or business preferred) or equivalent combination of relevant education and applicable job experience may be considered.
  • A minimum of 5 years progressively responsible experience in Pharmaceutical or Medical Sales and Learning & Development, with a minimum of 3 years in a training role.
  • A focus on specialty sales, rare diseases, pediatric neurology, neurology, pediatrics, and long-term care is beneficial.
  • Experience with product launches and developing new hire training plans is highly desired, along with extensive experience and technical expertise associated with access and reimbursement.
  • Medicare expertise is strongly preferred.
Responsibilities
  • Develops and maintains commercial training curriculum from the onboarding processes, new hire training, advanced training, and ongoing learning to meet the current and emerging needs of the field's commercial employees.
  • Responsible for developing, updating, and implementing all training modules, content, and programs appropriate for field commercial employees.
  • Creates training materials that enhance the learning process, including study guides, home study materials, assessments, frequently asked questions, competitive overviews, etc., and works with leadership and HR on follow-up and corrective action as appropriate.
  • Interfaces and collaborates with the marketing team to develop training and communications to support the brand strategy.
  • Development of materials, job aids, sales training backgrounders, competitive backgrounders, and market updates to support brand strategy.
  • Manage contracts and expenses with external consultants and vendors within budgetary guidelines.
  • Lead content development and maintain the Learning System, which includes training modules and materials, as well as live workshop content designed for a new hire.
  • Manages the approval of training materials and resources through Acadia’s MLR (Medical, Legal, and Regulatory) process, including regularly attending MLR meetings.
  • Works with corporate compliance and/or our compliance agency partner to ensure commercial field market access employees are trained and up-to-date on policies and procedures that affect their respective functional areas.
Desired Qualifications
  • Strong written communication skills.
  • Proven ability in creating effective learning & development materials.
  • Proven application of adult learning principles.
  • Demonstrated servant leadership.
  • Excellent facilitation skills in small and large groups.
  • Experience submitting and managing content for MLR approval prior to delivery.
  • Experience managing contracts and expenses with external vendors within budgetary guidelines.
  • Experience in launching a product (Sales, Managed Markets, and/or Learning & Development) is desirable.
  • Excellent interpersonal and communication skills.
  • Self-motivated and accountable to meet deadlines with minimal supervision.
  • History of intellectual curiosity.
  • Organization, initiative, and self-motivation.
  • Strong project management and vendor management experience.
  • Professionalism, integrity, and the ability to comply with strict policy, work in a highly regulated environment, and maintain confidential information and data.
  • Skilled at negotiating with business partners or management and influencing senior-level leaders regarding matters of significance to the organization.
  • Proficient at creating and communicating a clear vision among team members, effectively aligning resources and activities to achieve functional area and/or organizational goals.
Acadia Pharmaceuticals

Acadia Pharmaceuticals

View

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these conditions while also promoting diversity and inclusion within their operations.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1993

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased focus on personalized medicine benefits Acadia's tailored CNS therapies.
  • FDA's supportive regulatory environment aids Acadia's innovative CNS disorder treatments.
  • Growing interest in rare diseases supports Acadia's Rett syndrome treatment efforts.

What critics are saying

  • Increased competition from Biogen and Roche may impact Acadia's market share.
  • Litigation risks from class action lawsuit could lead to financial liabilities.
  • Challenges in DAYBUE's market adoption and reimbursement negotiations may affect commercialization.

What makes Acadia Pharmaceuticals unique

  • Acadia focuses on CNS disorders with a strong pipeline including pimavanserin.
  • The company collaborates with Biovail and Stoke Therapeutics for innovative drug development.
  • Acadia's DAYBUE is a pioneering treatment for Rett syndrome in the U.S.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Holidays

Paid Sick Leave

Paid Parental Leave

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
ETF Daily News
Mar 27th, 2025
Cibc World Markets Corp Invests $206,000 in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Cibc World Markets Corp invests $206,000 in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

Fierce Pharma
Dec 9th, 2024
Acadia nabs Lexicon, Bristol Myers Squibb veteran as new commercial lead

Acadia Pharmaceuticals has hired Big Pharma veteran Thomas Andrew Garner as its new chief commercial officer (CCO).

MarketWatch
Nov 26th, 2024
Acadia Pharmaceuticals in Exclusive License Agreement With Saniona for SAN711

Acadia Pharmaceuticals on Tuesday said it entered into an exclusive worldwide license agreement with Saniona to develop and commercialize SAN711.

World Pharmaceuticals
Oct 17th, 2024
Acadia gets Health Canada approval for Daybue to treat Rett Syndrome

US-based biopharmaceutical company Acadia Pharmaceuticals has received Health Canada marketing authorisation for Daybue (trofinetide) to treat a rare genetic neurological disorder.

PRWeb
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."